AtriCure Inc
Company Profile
Business description
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Contact
7555 Innovation Way
MasonOH45040
USAT: +1 513 755-4100
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
1,300
Stocks News & Analysis
stocks
Investors overly concerned about AI impact on ASX share
stocks
After earnings, is Palantir stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,139.90 | 34.50 | -0.38% |
| CAC 40 | 8,347.33 | 24.05 | 0.29% |
| DAX 40 | 25,013.41 | 1.46 | -0.01% |
| Dow JONES (US) | 50,135.87 | 20.20 | 0.04% |
| FTSE 100 | 10,350.43 | 35.80 | -0.34% |
| HKSE | 27,183.15 | 155.99 | 0.58% |
| NASDAQ | 23,238.67 | 207.46 | 0.90% |
| Nikkei 225 | 57,650.54 | 1,286.60 | 2.28% |
| NZX 50 Index | 13,513.68 | 67.31 | 0.50% |
| S&P 500 | 6,964.82 | 32.52 | 0.47% |
| S&P/ASX 200 | 8,867.40 | 44.20 | -0.50% |
| SSE Composite Index | 4,128.37 | 5.28 | 0.13% |